9 October 2009 - Meet with the Rhenovia Pharma Team at the 39th Meeting of the Society for Neuroscience, October 17-21, 2009, Chicago, Illinois, USA

Meet with the Rhenovia Pharma Team at the 39th Meeting of the Society for Neuroscience, October 17-21, 2009, Chicago, Illinois, USA

Michel Baudry, Ted Berger, Jean-Marie Bouteiller, Xiaoning Bi and Serge Bischoff present the unique RHENovia Modeling and Simulation (RHENOMS) platform for the optimization of the Drug Discovery and Development Process  of pharmaceutical and biotechnology companies. Modeling the brain: from synapse to neuron
AUTHOR BLOCK: *S. L. ALLAM1, R. GREGET2, N. AMBERT2, J.-M. BOUTEILLER3, M. BAUDRY4, S. BISCHOFF2, T. W. BERGER3;
1Univ. of Southern California, Los Angeles, CA; 2Rhenovia Phrama, Mulhouse Cedex, France; 3Biomed. Engg., 4Biol. Sci., USC, Los Angeles, CA

Functional simulation of excitatory synaptic transmission: A new technology for innovative CNS drugs and synergistic combinations
AUTHOR BLOCK: R. GREGET1, N. AMBERT1, M. BAUDRY2, T. W. BERGER3, J.-M. C. BOUTEILLER3, *S. BISCHOFF1;

Memantine interactions with NMDA receptors: Modeling and simulation studies of the effect of frequency and membrane potential
AUTHOR BLOCK: N. AMBERT1, R. GREGET1, S. BISCHOFF1, T. W. BERGER2, *J.-M. C. BOUTEILLER2, M. BAUDRY3;



 
PRESS RELEASE

Mulhouse, France,  2009:
Rhenovia opens its biosimulation platform for
collaborative projects to optimize CNS drug discovery
and development
Rhenovia's RHEDDOS program enables pharmaceutical and
biotechnology companies to simulate CNS pathologies to identify
molecular targets and improve drug efficacy